Tema Etfs LLC Cuts Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Tema Etfs LLC cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 18.1% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 5,301 shares of the biopharmaceutical company’s stock after selling 1,174 shares during the quarter. Tema Etfs LLC’s holdings in Alnylam Pharmaceuticals were worth $1,729,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at about $243,000. Mutual of America Capital Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 673.9% in the 1st quarter. Mutual of America Capital Management LLC now owns 13,644 shares of the biopharmaceutical company’s stock valued at $3,684,000 after purchasing an additional 11,881 shares in the last quarter. Cetera Investment Advisers grew its holdings in shares of Alnylam Pharmaceuticals by 68.1% during the 1st quarter. Cetera Investment Advisers now owns 8,017 shares of the biopharmaceutical company’s stock worth $2,165,000 after purchasing an additional 3,247 shares during the period. LPL Financial LLC grew its holdings in shares of Alnylam Pharmaceuticals by 11.3% during the 1st quarter. LPL Financial LLC now owns 20,679 shares of the biopharmaceutical company’s stock worth $5,584,000 after purchasing an additional 2,107 shares during the period. Finally, XTX Topco Ltd acquired a new stake in Alnylam Pharmaceuticals during the 1st quarter worth approximately $402,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Down 1.7%

NASDAQ:ALNY opened at $465.34 on Friday. The company has a market cap of $61.48 billion, a PE ratio of 1,938.92 and a beta of 0.30. The business’s 50 day moving average is $456.55 and its two-hundred day moving average is $401.08. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ALNY shares. BMO Capital Markets lifted their price target on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. HC Wainwright set a $570.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 4th. Truist Financial upped their price target on shares of Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Wall Street Zen raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 10th. Finally, Royal Bank Of Canada upped their target price on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a research report on Friday, September 19th. Twenty-three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $482.17.

Insider Activity

In related news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the completion of the sale, the executive vice president owned 21,264 shares of the company’s stock, valued at $9,615,155.52. This represents a 36.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Yvonne Greenstreet sold 10,000 shares of the stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $451.27, for a total transaction of $4,512,700.00. Following the sale, the chief executive officer owned 65,409 shares in the company, valued at approximately $29,517,119.43. This trade represents a 13.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 78,328 shares of company stock valued at $35,705,793 over the last quarter. 1.50% of the stock is owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.